Skip subpage navigation
Nov. 6-7, 2019
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: July 29, 2019
- Pre-Proposal Teleconference: August 12, 2019 @ 11:00 a.m. Central
- Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
- UF BPA & UF ADP Quotes Due: Sept. 20, 2019
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- INSULINS - RAPID-ACTING AGENTS:
- Admelog
- Admelog Solostar
- Afrezza
- Apidra
- Apidra Solostar
- Fiasp
- Humalog
- Humalog Junior Kwikpen
- Humalog Kwikpen U-100
- Insulin Lispro
- Insulin Lispro Kwikpen U-100
- Novolog
- Novolog Flexpen
- PHOSPHODIESTERASE-5 INHIBITORS - ERECTILE DYSFUNCTION:
- Cialis
- Levitra
- Staxyn
- Stendra
- Viagra
|
- Annovera
- Baqsimi
- Drizalma Sprinkle
- Duaklir Pressair
- Gvoke
- Inrebic
- Katerzia
- Nayzilam
- Nourianz
- Nubeqa
- Rinvoq ER
- Rozlytrek
- Rybelsus
- Temixys
- Thiola EC
- Tosymra
- Turalio
- Vyleesi
- Wakix
- Xenleta
- Xpovio
- Zelnorm
|
|
August 7-8, 2019
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: April 26, 2019
- Pre-Proposal Teleconference: May 13, 2019 @ 1100 Central
- Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
- UF BPA & UF ADP Quotes Due: June 21, 2019
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- MULTIPLE SCLEROSIS AGENTS - INTERFERON:
- Avonex
- Betaseron
- Extavia
- Plegridy
- Rebif
- MULTIPLE SCLEROSIS AGENTS - METHYL FUMARATE:
- CORTICOSTEROIDS-IMMUNE MODULATORS - HIGH POTENCY:
- Bryhali
- Cordran Tape
- Impoyz
- Lexette
- Ultravate
|
- Adhansia XR
- Balversa
- Cutaquig
- Dovato
- Duobrii
- Egaten
- Emgality
- Evekeo ODT
- Ezallor
- Jornay PM
- Nucala
- Piqray
- Ruzurgi
- Skyrizi
- Slynd
- Sunosi
- Vyndaqel
|
|
May 8-9, 2019
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: Feb. 01, 2019
- Pre-Proposal Teleconference: February 11, 2019 @ 11:00 a.m. Central
- Clinical/Cost Presentation Meeting Window: February - March 2019
- UF BPA & UF ADP Quotes Due: March 29, 2019
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- PROTON PUMP INHIBITORS - ALTERNATIVE DOSAGE FORMS:
- Aciphex Sprinkle
- Nexium Packet
- Prevacid SoluTab
- Protonix Packets
- Zegerid Powder
- PROTON PUMP INHIBITORS - CAPSULES AND TABLETS:
- PULMONARY ARTERIAL HYPERTENSION - ENDOTHELIN RECEPTOR AGONIST:
- Letairis
- Opsumit
- Tracleer
- PULMONARY ARTERIAL HYPERTENSION - PROSTACYCLIN NEBULIZED THERAPY:
- PULMONARY ARTERIAL HYPERTENSION - PROSTACYCLIN ORAL THERAPY:
- PULMONARY ARTERIAL HYPERTENSION - SOLUBLE GUANYLATE CYCLASE STIMULATOR:
|
- Apadaz
- Bijuva
-
Diacomit
-
Inbrija
-
Lotemax SM
-
Mavenclad
-
Mayzent
-
Motegrity
-
Prograf
-
Qmiiz ODT
-
Rocklatan
-
Symjepi
-
Tirosint-SOL
|
|
Feb. 6-7, 2019
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: Nov. 01, 2018
- Pre-Proposal Teleconference: November 06, 2018 @ 11:00 a.m. Central
- Clinical/Cost Presentation Meeting Window: November - December 2018
- UF BPA & UF ADP Quotes Due: Dec. 21, 2018
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- INSULINS - RAPID ACTING AGENTS: -- Solicitation Cancelled
- Admelog
- Admelog Solostar
- Afrezza
- Apidra
- Apidra Solostar
- Fiasp
- Humalog
- Humalog Junior Kwikpen
- Humalog Kwikpen U-100
- Humalog Kwikpen U-200
- Novolog
- Novolog Flexpen
- MIGRAINE AGENTS - CGRP PREVENTATIVE:
- ONCOLOGICAL AGENTS - 2ND-GEN ANTIANDROGENS:
- ONCOLOGICAL AGENTS - CYP-17 INHIBITORS:
|
- Abilify Mycite
- Aemcolo
-
Arakoda
-
Bryhali
-
Cequa
-
Daurismo
-
Firdapse
-
Granix vials
-
Inveltys
-
Krintafel
-
Lexette
-
Lorbrena
-
Nocdurna
-
Nuzyra
-
Oxervate
-
Revcovi
-
Ryclora
-
Seysara
-
Sympazan
-
Talzenna
-
Tegsedi
-
Tiglutik
-
Tolsura
-
Udenyca
-
Vitrakvi
-
Xelpros
-
Xofluza
-
Xospata
-
Xyosted
-
Yupelri
|
|
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: April 25, 2024